At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 518 enrolled
Drug / intervention
Besivance +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days
In Brief
A Phase 3 clinical trial evaluating Besivance and Vehicle for Bacterial Conjunctivitis. Completed, enrolled 518 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedAug 2010
Primary CompletionDec 2011
Study CompletionFeb 2012
TodayJul 2026
First PostedAug 5, 2010
Enrollment StartJun 1, 2010
Primary CompletionDec 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 15.9 years ago
Interventions
Besivancedrug
Ocular administration to affected eye for 7 days
Vehicledrug
Vehicle of Besivance administered to affected eye for 7 days